NCT05986682 · OUTCOME

Hospice Care Given Prior to Death

Real-World Analysis of Belantamab Mafodotin Care Patterns in Patients With Relapsed and/or Refractory Multiple Myeloma · Source last updated 2025-02-03

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: COUNT_OF_PARTICIPANTS
Unit: Participants
Interval / dispersion: Not reported
Time frame: Between baseline and earliest of end of BLENREP treatment, death, lost to contact or end of study timeframe, up to 40 months.

What was measured

The number and percentage of patients who were in Hospice Care prior to death. Analyzed for the 10 patients who died as of last follow-up Dec. 1st 2023.

Groups in this outcome

Multiple Myeloma/Blenrep Participants Who Died

Participants with relapsed and/or refractory multiple myeloma who were treated with Belantamab Mafodotin - blmf (BLENREP) in the DCI Oncology outpatient clinics between August 5, 2020 and November 7, 2023; and who died prior to December 1, 2023.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Multiple Myeloma/Blenrep Participants Who Died	10

Reported measurements

Yes

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Multiple Myeloma/Blenrep Participants Who Died	4	Not reported	Not reported	Not reported	Not reported

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Multiple Myeloma/Blenrep Participants Who Died	5	Not reported	Not reported	Not reported	Not reported

Unknown

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Multiple Myeloma/Blenrep Participants Who Died	1	Not reported	Not reported	Not reported	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
value
4
title
Yes
categories
measurements
group Id
OG000
value
5
title
No
categories
measurements
group Id
OG000
value
1
title
Unknown

denoms

counts
group Id
OG000
value
10
units
Participants

description

The number and percentage of patients who were in Hospice Care prior to death. Analyzed for the 10 patients who died as of last follow-up Dec. 1st 2023.

groups

description
Participants with relapsed and/or refractory multiple myeloma who were treated with Belantamab Mafodotin - blmf (BLENREP) in the DCI Oncology outpatient clinics between August 5, 2020 and November 7, 2023; and who died prior to December 1, 2023.
id
OG000
title
Multiple Myeloma/Blenrep Participants Who Died

param Type

COUNT_OF_PARTICIPANTS

reporting Status

POSTED

time Frame

Between baseline and earliest of end of BLENREP treatment, death, lost to contact or end of study timeframe, up to 40 months.

title

Hospice Care Given Prior to Death

type

POST_HOC

unit Of Measure

Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice